Analysis of the temporal compressibility of breast tumour marker assays: development of a "near patient" assay.
The aim of this study was to investigate whether immunoassays for circulating MUC1 antigen in breast cancer could be compressed in time so that serum level results would be made available during the time of the patient's visit to clinic. Two assays were used: -The EMCA (Euro DPC) is a liquid phase immunoassay and the ELSA CA15-3 (CIS) is a double determinant solid phase immunoradiometric assay. The effects of shortened incubation times were investigated by assaying standards and unknown samples and comparing the results with those using the standard kit protocols. The binding kinetics of the monoclonal antibodies employed in the assays were analysed separately. We conclude that the EMCA assay can be shortened to 35 min and we have attributed this to the fast binding kinetics inherent in a liquid phase assay. This shortened assay may produce the basis for a useful "near patient" assay. By comparison, the solid phase ELSA CA15-3 assay cannot be compressed without loss in assay performance.
Murray
A
A
Department of Pharmaceutical Sciences, University of Nottingham, U.K.
Robertson
J F
JF
Price
M R
MR
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood*; D005260:Female; D006801:Humans; D007118:Immunoassay / Q000379:methods; D015592:Immunoradiometric Assay / Q000379:methods; D007700:Kinetics; D018396:Mucin-1 / Q000097:blood*; D011933:Reagent Kits, Diagnostic; D015203:Reproducibility of Results; D013997:Time Factors
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D018396:Mucin-1; D011933:Reagent Kits, Diagnostic